Care
The partnerships come in the wake of an eight-year legal battle in which IQVIA accused Veeva of stealing trade secrets.
The acquisition expands Teladoc's specialist network and presence in the region, while the company navigates ongoing financial challenges.
ArteraAI Prostate uses digital pathology images from a patient’s biopsy to predict potential long-term outcomes of their prostate cancer.
The companies will develop AI models trained on real-world data to help identify and diagnose patients with paroxysmal nocturnal hemoglobinuria.
ArteraAI Prostate forecasts potential long-term outcomes of a patient's prostate cancer biopsy slide based on digital pathology images.
The financing comes on top of the company's $900 million annual research and development investment in the U.S.
The company plans to launch the first version of its AI Advocate tool, aimed at helping patients manage and guide their overall healthcare, in the third quarter of this year.
The alliance aims to benefit patients with chronic conditions and allow real-time interoperability among healthcare providers, pharmacies and payers.
The feature will be available via new iOS and watchOS updates, one year after the U.S. International Trade Commission banned Apple from selling its Series 9, Series 10 and Ultra 2 watches.
The company will use the funds to expand its technology offerings and nationwide partnerships.